A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (NuvigilÂ®) To Reduce Cancer-Related Fatigue in Patients With High Grade Glioma
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 20 May 2019
Price : $35 *
At a glance
- Drugs Armodafinil (Primary)
- Indications Fatigue
- Focus Therapeutic Use
- 14 May 2019 Status changed from recruiting to active, no longer recruiting.
- 24 Jun 2016 Planned primary completion date changed from 1 Mar 2016 to 1 May 2020.
- 03 Jul 2014 New trial record